Trials / Recruiting
RecruitingNCT07288333
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Neurocrine Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NBI-1117570 | Oral administration |
| DRUG | Placebo | Oral administration |
Timeline
- Start date
- 2026-02-16
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
- First posted
- 2025-12-17
- Last updated
- 2026-04-15
Locations
2 sites across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07288333. Inclusion in this directory is not an endorsement.